Getting innovation from lab to market is not an easy feat, and few countries do it well. Australia’s research output, for instance, punches way above its commercial applications (e.g. #10 in the SJR ranking and Nature Index).

Are there ways to accelerate that transformation? Australia set up Main Sequence Ventures (@mseqvc) as a AU$240M (about US$170M) deep tech fund backed by the CSIRO and private investors, to target that opportunity notably in domains such as ag-tech, synthetic biology, quantum and space (the CSIRO is the Australia’s federal government agency responsible for scientific research).

This podcast is hosted by Benjamin Joffe, Partner at SOSV, a global early stage fund focused on deep tech. SOSV runs multiple accelerator programs including HAX (intelligent hardware) and IndieBio (life sciences). To hear about new episodes, sign up to the newsletter or follow us on twitter at @LabToMarket.

For other episodes on foreign deep tech ecosystems, check out India and Japan.

OVERVIEW

In this episode, Phil Morle (@philmorle), partner and long-time pioneer of the country’s startup scene (wikipedia), explains the commonalities he found between entrepreneurs and scientists, how the fund extended its investment domains and helps compress development timelines.

He closes with thoughts on the tough year it has been with fires, drought and Covid, and how returns and impact now go hand in hand, from responding to new threats, feeding the planet, to delivering healthcare at scale.

Before Main Sequence Ventures, Phil had three lives:

• He spent a decade as a theatre director, learning how to create things from scratch.

Among the lessons learned:

• How he got scientists to grow an entrepreneurial mindset.

PREVIOUS EPISODES

• Habib Haddad and Calvin Chin (E14 Fund of MIT Media Lab) on Funding Science Fiction That Works

RESOURCES ON DEEP TECH

• DeepTech Investing Report by Different

SUBSCRIBE

• Podcast: Apple Podcast, Spotify, other platforms